LivaNova plc (NASDAQ: LIVN) reported Q3 EPS of $0.78, $0.12 worse than the analyst estimate of $0.90. Revenue for the quarter came in at $272.1 million versus the consensus estimate of $275.03 million.

"The third quarter results reflect our continued momentum in accelerating our sales growth while making significant investments to deliver on our long-term strategy. Results for third quarter 2018 were strong across all regions," said Damien McDonald, Chief Executive Officer of LivaNova. "Neuromodulation had another exceptional quarter of double-digit growth in all regions. Cardiovascular also performed well, driven by our oxygenator and autotransfusion businesses. Profitability in the quarter was impacted by higher than expected site activation for our ANTHEM-HFrEF Heart Failure pivotal trial. We remain confident in our ability to deliver on our 2018 guidance while aggressively investing in future growth to deliver quality care to more patients around the world."

GUIDANCE:

LivaNova plc sees FY2018 EPS of $3.50-$3.70, versus the consensus of $3.61.

For earnings history and earnings-related data on LivaNova plc (LIVN) click here.